Madrigal Pharmaceuticals, Inc. (MDGL) Q4 2019 Earnings Results

Madrigal Pharmaceuticals Misses on EPS, Stock Down 1.23%

Madrigal Pharmaceuticals reported a loss per share of $1.80, which did not meet any consensus expectations. The stock reacted negatively, declining by 1.23%. Investors may be concerned about the lack of revenue information and forward guidance, which could indicate uncertainty about the company's future performance.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-1.80	N/A	N/A
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Defensive

Management expressed a cautious outlook, emphasizing ongoing efforts in clinical development. They did not provide specific guidance for future performance.

Management did not provide specific revenue guidance for the upcoming quarters.

The company remains focused on advancing its clinical programs despite the current financial results.

Madrigal Pharmaceuticals Misses on EPS, Stock Down 1.23%

Key numbers

Management commentary

Madrigal Pharmaceuticals, Inc.

More earnings this week

Madrigal Pharmaceuticals Misses on EPS, Stock Down 1.23%

Key numbers

Management commentary